文档介绍：Combined-Modality Treatment for High Risk TCC of the Bladder
Pu Jin-Xian, Wen Duan-Gai, Ping Ji-Gen, Yuan He-Xing
Dept. of Urol.
1st Affiliated Hospital, Soochow University
Suzhou,China
Abstract-Objective To identify the ideal antitumor drugs monthly for 3 circles were
therapy for high risk bladder cancer with good kept only for multiple, recurrent and locally
survival and quality. Methods Between advancd tumors. Results 90 patients were
January 1997 and November 2006, 111 followed up for months(12-60 months).
patients(86 males and 25 females) with The 2 years recurrence rate is 30%(27/90).
histologically confirmed transitional cell The overall survivals are % at 3 year and
carcinoma were enrolled. Median age was 61 % at 5 years, respectively. Conclusion
years (range,37-78 years). 45 patients had TURBT, partial or total cystectomy could be
T1G3 lesions(included multiple,8; recurrence, choosed for bladder tumors of T1G3, multiple,
16). 66 had T2, T3, and T4. All patients recurrenced and T2-T4 to plete
plete transurethral resection of resection of tumor, followed by arterial or
the bladder tumor (TURBT), partial systemic chemotherapy early after
cystectomy and radical cystectomy at our operation and intravesical chemotherapy for
institution. 3 circles systemic chemotherapy up to 2 years. It is an effective treatment for
with